Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, M. A. von Wichmann, Esteban Ribera et al.|Clinical Infectious Diseases|2017Cited by 103
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be SignificantJuan Berenguer, Jordi Navarro, María Jesús Téllez et al.|Open Forum Infectious Diseases|2018Cited by 28
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019Chiara Fanciulli, Juan Berenguer, Carmen Busca et al.|HIV Medicine|2022Cited by 28
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched studyDaniel K. Nomah, Maribel Tamayo, Juliana Reyes‐Urueña et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 20
Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label TrialAdrián Curran, Manuel Crespo, Anna Rull et al.|Journal of Clinical Medicine|2020Cited by 15